论文部分内容阅读
目的探讨左西孟旦治疗扩张型心肌病(DCM)失代偿患者血浆N末端B型脑钠肽前体(NT-proBNP)表达变化及心功能的影响。方法 56例DCM失代偿患者,随机分为对照组(31例)和治疗组(25例)。对照组采用常规治疗,治疗组在常规治疗基础上加用左西孟旦治疗,比较两组疗效。结果治疗组患者有效23例,有效率为92.0%,对照组患者有效27例,有效率为87.1%,两组有效率比较差异无统计学意义(χ~2=0.348,P>0.05)。治疗后,治疗组NT-proBNP浓度显著低于对照组,左心室射血分数(LVEF)高于对照组,差异具有统计学意义(P<0.05),两组左室舒张末内径比较,差异无统计学意义(P>0.05)。结论左西孟旦可有效改善DCM失代偿患者症状,进一步降低患者血浆NT-proBNP浓度和改善心脏收缩功能,值得借鉴。
Objective To investigate the effect of levosimendan on plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) expression and cardiac function in patients with decompensated dilated cardiomyopathy (DCM). Methods 56 patients with decompensated DCM were randomly divided into control group (31 cases) and treatment group (25 cases). The control group were treated with conventional therapy, the treatment group on the basis of conventional treatment plus levosimendan treatment, the efficacy of the two groups were compared. Results The effective rate of the treatment group was 23 cases, the effective rate was 92.0%. The effective rate was 87.1% in the control group. There was no significant difference between the two groups (χ ~ 2 = 0.348, P> 0.05). After treatment, the concentration of NT-proBNP in the treatment group was significantly lower than that in the control group, and the left ventricular ejection fraction (LVEF) was higher than that in the control group (P <0.05). The left ventricular end-diastolic diameter Statistical significance (P> 0.05). Conclusion Levosimendan can effectively improve the symptoms of patients with decompensated DCM, further reduce the plasma concentration of NT-proBNP and improve cardiac contractility, it is worth learning from.